Insurance Stopped Covering Zepbound? What to Do Before Your Next Refill — and What It Costs Now

If your insurance stopped covering Zepbound, get the reason in writing first: an expired approval, denied renewal, drug-list change, or lost weight-loss coverage. Each needs a different request. Eligible LillyDirect single-dose vial or KwikPen cash offers cost $299–$449 per 28 days, with a 45-day purchase rule at higher doses. Medicare's Bridge costs $50 per fill if you qualify.

Two things changed this fall. CVS Caremark put Zepbound back on its most common commercial drug lists on October 1, 2026, for employers and other plan sponsors that choose to cover it. So a denial from last year may not be the final word. And all of Lilly's current Zepbound savings cards end December 31, 2026.

Here's the catch most people miss: Zepbound prices depend on both the device and the payment program. The $25 card is for the single-dose pen. Medicare's $50 is for the KwikPen only. The table below shows which price fits you.

RX Index Decision Verdict: Get the exact written reason and your next refill date, then line up a way to pay so a paperwork fight doesn't turn into a gap in doses.

• Best for: Adults whose plan paid for Zepbound before and now rejects a refill, charges much more, or has sent a notice that coverage is ending.
• Not ideal for: People who never had coverage (start with does insurance cover Zepbound for weight loss). If you're under 18, pregnant or planning a pregnancy, or have type 1 diabetes or an eating-disorder history, take this to your treating clinician first. Do the same if you have a personal or family history of medullary thyroid cancer or MEN 2, a past serious allergic reaction to tirzepatide or Zepbound's ingredients, or were told by a clinician not to use Zepbound.
• The factor that matters most: The written reason payment stopped — and which Zepbound device you use. Together, they decide your fix and your price.

Your 7 paths after Zepbound coverage stops

There are seven real ways forward. The first four try to get your plan paying again. The last three are ways to pay if it won't. Most people should try the top of the list first, and line up a backup from the bottom while they wait.

Prices checked October 21, 2026, from Lilly's full program terms and CMS. Medicine only — needles, syringes, your prescriber's fees, and any applicable taxes or fees are extra.

The right next step isn't the same for everyone. It depends on your state, your plan and its drug list, whether you'd stay on Zepbound or consider another medicine, injection or pill, FDA-approved or compounded, and your budget. The RX Index's Find My GLP-1 Path tool is free, takes about 2 minutes, and needs no signup. Answer a few quick questions and see the GLP-1 paths and providers that fit your goals, budget, insurance, and situation. It can't tell you whether your plan will pay — only your plan can.

See which GLP-1 path fits you

Insurance stopped covering Zepbound: what should I check first?

First, find out whether the pharmacy claim was rejected or went through at a higher price. Then get the exact reason in writing. An approval problem, a drug-list change, and a plan that excludes weight-loss drugs each need a different request.

A few words first, so the rest makes sense:

• Prior authorization (PA) is a permission slip from your insurer. The plan has to say yes before it pays.
• Formulary is your plan's list of covered drugs.
• Benefit exclusion is a plan rule that leaves a drug, or a use of a drug, out of coverage for everyone on the plan.
• PBM (pharmacy benefit manager) is the company that runs your drug benefit, like CVS Caremark, Express Scripts, or OptumRx. For an employer plan, the employer chooses its benefits and the PBM runs the drug claims.

Step 1: Put your records side by side

Write down what you know. If something is missing, write "unknown" and ask for it. Blank means unknown — not "not covered."

Step 2: Match what you were told to the right request

This table points you to the right request. It isn't a ruling on your claim. Only your plan's written decision is.

Find your row and your price

The sorter below does the matching for you and pulls the price that fits your device and dose. The tables on this page show everything with or without it.

Want to see it in action? Say you're 52, on 10 mg single-dose pens through your employer, and your open-enrollment packet says weight-loss drugs end January 1. That's the "coverage ends January 1, 2027" row: ask HR for the rule and any add-on coverage, and ask your prescriber for a plan before your last covered fill. For planning, today's uncovered-pen card is as low as $499 per 28 days if you qualify. A 10 mg single-dose vial or KwikPen has a $449 cash offer; after the first eligible purchase, the next purchase must be within 45 days of delivery. At $449, 13 single-dose-vial fills would total $5,837. But today's cards end December 31, 2026: these figures aren't a confirmed quote for your January 2027 refill. That's a made-up example, not a real reader.

Why did my insurance stop covering Zepbound?

Zepbound coverage can end for any of these five reasons: the plan dropped weight-loss drugs, the plan or its PBM switched its preferred drug, a renewal was denied, the approval ran out, or the whole policy ended. Cost is one reason plans give. The exact words on your notice tell you which one you have.

Here's what that looks like in real plans:

• A drug-list switch, then a reversal. CVS Caremark changed its main commercial drug lists to prefer Wegovy on July 1, 2025; affected plans removed Zepbound (CVS announcement; one employer's notice). On October 1, 2026, it added Zepbound back as an additional preferred option — for employers and other plan sponsors that choose to cover weight-loss drugs (CVS Health, May 28, 2026).
• An approval cut short, with exceptions. California's Medi-Cal ended weight-loss coverage on January 1, 2026, and earlier approvals ended December 31, 2025. But its notice preserves routes for medically necessary care under age 21 and some timely hearing requests. Requests for sleep apnea are still possible (Medi-Cal Rx notice).
• Different dates within one program. Massachusetts' Group Insurance Commission ended weight-only GLP-1 coverage after June 30, 2026, for its non-Medicare plans. Its Medicare plans end that coverage after December 31, 2026 (GIC benefits guide, page 3).
• More changes for 2027. In Mercer's 2026 survey, 5% of employers with 500 or more workers said they planned to drop weight-loss GLP-1 coverage in 2027 or were actively considering it. See our employer coverage tracker for named plans.

The takeaway: the company on your card may run the claims; for an employer plan, your employer chooses its benefits. That's why two people "on CVS Caremark" can get two different answers.

Did CVS Caremark bring Zepbound back?

Yes, for some plans. CVS Caremark added Zepbound back to its most common commercial drug lists as an additional preferred option on October 1, 2026, but only for employers and other plan sponsors that choose to cover weight-loss drugs. Lilly's own coverage page now says coverage "has been restored" on select CVS Caremark drug lists (Lilly).

If your coverage stopped in the 2025 Caremark switch, check again before you pay cash:

1. Log in at caremark.com and search "Zepbound" by your exact device and dose.
2. Read the status word: covered, prior authorization required, not on formulary, or excluded.
3. Ask HR, or your plan if you do not have employer coverage: "Did our plan adopt CVS Caremark's October 1, 2026 update, and do we cover weight-loss drugs?"

If it's covered again, the $25 card may apply to the single-dose pen. You'll likely still need a new prior authorization. A 2025 rejection is a reason to recheck — not proof you're covered now. For the approval rules, see CVS Caremark Zepbound prior authorization.

What should I do before my next refill?

Send your prescriber your coverage notice, your next refill date, and the date of your last dose. If a gap could happen, ask for a plan before your next scheduled dose. Your prescriber decides what happens after a gap — not your insurer, and not this page.

Think of it as three people with three jobs. The pharmacy can show how the claim went through. Your prescriber supplies the medical records. Your plan decides what its benefit pays.

For a missed dose, check the current Zepbound prescribing information (revised August 2026) and ask your prescriber or pharmacist what to do. For a longer gap, the label doesn't give a restart plan. That's your prescriber's call.

Why staying on track matters: in the SURMOUNT-4 trial, adults who had already been on tirzepatide for 36 weeks, reaching a tolerated 10 or 15 mg dose, and were then switched to a placebo gained an average of 14% of their week-36 body weight over the next 52 weeks. Those who stayed on it lost another 5.5% on average from their week-36 weight (JAMA, 2024). That trial was in adults with obesity or overweight without diabetes. It doesn't predict what a short gap will do for you. More in weight regain after stopping Zepbound.

Don't stretch, skip, or space out doses on your own to make a supply last. Call your prescriber.

Two scripts you can use today

To your insurer or PBM (the number on your card):

My plan paid for Zepbound before, and this refill came back differently. Was the claim rejected, or covered with a higher amount I owe? What exactly was billed — which device and dose? Is the problem an expired approval, renewal criteria, this drug or device, or a benefit that ended? Which rule changed, when did it start, and can you send it in writing? What can my prescriber submit, where, and by when? Is any temporary fill available while it's reviewed? Can I have a reference number for this call?

To your prescriber (through the patient portal or usual secure message):

My Zepbound coverage changed. My next refill is due [date] and my last dose was [date]. I can send the pharmacy's reason, my old approval, and the plan's notice. Could your team check whether this needs a claim fix, a renewal, an exception, or an appeal? If the plan asks for renewal records, please include my records from before I started treatment. If there may be a gap, what's my care plan? I'd also like to talk about what I can afford if the plan won't pay.

Write down who you talked to, the date, the reference number, and what they promised. Written answers beat phone promises.

Can I get my Zepbound coverage back?

Sometimes. It depends on why payment stopped. An expired approval or a missing record can often be fixed with a renewal. A drug-list change may be fixed with an exception. A plan-wide exclusion usually can't be reversed by proving you need the drug, but you can still ask whether the rule was applied to you correctly.

An old approval helps, but it isn't a promise. If the plan itself changed, an approval with a future end date may stop working anyway — that happened to Medi-Cal members at the end of 2025, with the exceptions described below.

If your approval expired or your renewal was denied

Ask for the plan's current continuation criteria (the rules for staying on a drug) and which rule your request failed. Missing records and not meeting a rule are different problems with different fixes.

Your prescriber should answer the plan's rule point by point: starting weight, current weight, percent lost, and dose history. For more, see initial vs. renewal prior authorization, how to appeal a Zepbound denial under your plan's rules, and the free GLP-1 appeal letter template. Lilly also offers a letter of medical necessity and appeals guide your doctor can adapt.

Review deadlines vary. Many plans follow federal rules that give you 180 days to file an internal appeal after a denial (HealthCare.gov), so check the deadline on your notice against your plan's review rules. Ask the plan to correct a notice that conflicts with those rules. If waiting could seriously harm your health, ask your clinician whether a faster (expedited) review fits.

If your BMI is lower now

Your current BMI alone doesn't tell you whether you meet renewal rules. The CVS Caremark and Cigna policies below judge continuation in part on how you've done since you started, measured from your weight before treatment.

Two real examples:

Those are two published policies, not proof of your own benefit. Other criteria apply. If your renewal was denied after you lost weight, start with the records: make sure the plan saw your weight from before you started.

If the plan dropped weight-loss drugs

A benefit exclusion leaves a whole category out of coverage. A medical letter or a new prescriber usually can't add it back. What you can still do:

• Ask for the exact rule, which plan or group it covers, and the date it starts.
• Ask HR whether your employer bought add-on coverage (some insurers sell it as a "rider") or allows any exception. Our guide on asking your employer to cover GLP-1s has wording.
• Ask whether the rule was applied to you correctly, and what review rights you have.

The difference between an exclusion and a denied approval is laid out in plan exclusion vs. prior authorization.

If you have sleep apnea

This is the door that's unique to Zepbound. Zepbound is FDA-approved to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity (label). Some plans that exclude weight loss still allow requests for this use — Medi-Cal says so in writing.

Cigna's policy, for example, asks for a study showing at least 15 breathing events per hour and a BMI of 30 or higher at baseline (Cigna IP0816). This only applies if you truly have the diagnosis — it's something your clinician documents, never a billing trick. More in does insurance cover Zepbound for sleep apnea.

If you have type 2 diabetes

Mounjaro contains tirzepatide, the medicine in Zepbound, and is FDA-approved for type 2 diabetes (Mounjaro label). Ask your plan for its diabetes-drug coverage rules. Whether it fits you is your prescriber's decision. See switching from Zepbound to Mounjaro.

If the plan just prefers a different drug

If your notice says "use Wegovy" or another preferred drug, you have two honest options: ask your prescriber whether the covered drug fits you, or ask for a formulary exception. An exception is stronger when your records show a real reason — for example, the preferred drug didn't work for you or you couldn't tolerate it. Your clinician documents what actually happened; nothing gets invented. If you do switch, see switching from Zepbound to Wegovy.

Did my plan have to warn me?

Sometimes, and the timing depends on the rule and the plan type. For employer plans covered by ERISA, a federal benefits law, a summary of a major benefit cut is usually due within 60 days after it's adopted. A separate rule requires 60 days' notice before certain changes made outside renewal.

The details, in plain words:

• Notice after adoption: Employer plans covered by ERISA must send a summary of a "material reduction" in benefits within 60 days after adopting it. Plans that send updates on a regular cycle of 90 days or less can use that cycle instead (29 CFR 2520.104b-3).
• Advance notice for changes outside renewal: A material change that affects your Summary of Benefits and Coverage (SBC), isn't in your latest SBC, and happens outside renewal must be announced at least 60 days before it starts (29 CFR 2590.715-2715). Changes made at your plan's renewal don't trigger this particular rule, but renewal disclosure rules still apply.

What to do: email HR for your Summary Plan Description, the notice of the change, and whether the plan is self-funded (the employer pays claims itself) or fully insured (the employer buys a policy). In the same email, ask whether a one-time transition fill is available. It's worth asking, but it isn't guaranteed. This is general information, not legal advice.

Does my insurance type change the next step?

Yes. Your insurance type decides who handles a Zepbound coverage loss and which rules apply. Follow the rules of the program that actually covers you.

Employer, Marketplace, or individual plans

Start with the records and scripts above, and the HR steps if you have an employer plan. If your whole job-based plan ended, ask about COBRA, which can let you keep that plan for a while. Losing job-based coverage generally lets you pick a Marketplace plan during the 60 days before or after the loss; losing coverage for one drug doesn't (HealthCare.gov).

Medicare

The Medicare GLP-1 Bridge charges eligible people $50 per fill for Zepbound used for weight management. It runs July 1, 2026, through December 31, 2027. For Zepbound, it covers only the KwikPen — not vials or single-dose pens (CMS).

To qualify, you need an eligible Part D plan, such as a standalone drug plan or a Medicare Advantage HMO or PPO with drug coverage. Not every Medicare plan type qualifies; CMS lists the eligible types. You must be 18 or older, follow an ongoing food-and-activity plan, and have met one of these when you first started a GLP-1 — even if that was before Medicare:

Three exceptions that matter for Zepbound:

• If you filled a GLP-1 prescription covered through Part D in 2026, including supplemental coverage from an employer or union retiree Part D plan, you can't use the Bridge in 2026. CMS hasn't said yet how this will work in 2027 (CMS Part D guidance).
• If you have moderate-to-severe obstructive sleep apnea, type 2 diabetes, or MASH with moderate-to-advanced liver scarring but no cirrhosis, the Bridge isn't for you. Those uses go through your regular Part D plan and its prior authorization. A Part D denial doesn't make the Bridge available.
• The $50 doesn't count toward your Part D out-of-pocket limit, and Extra Help doesn't lower it. Pen needles aren't covered.

How it works: your prescriber sends a KwikPen prescription to your pharmacy, and the pharmacy asks the prescriber to submit the approval request. CMS says the decision comes within 72 hours after that request is submitted. There's no formal appeal inside the Bridge, but your prescriber can resubmit with corrected or new information. Approval lasts through December 31, 2027, including refills and dose changes, while you remain eligible. Changing GLP-1s needs a new approval; a later Part D-covered GLP-1 fill or move to an ineligible plan type can end Bridge access (CMS pharmacy guidance; Medicare.gov). Each fill is one 28- or 30-day supply; 60- and 90-day fills aren't available. Questions: 1-800-MEDICARE.

Say you turned 65 in September. You started Zepbound in 2024 at a BMI of 37, and it's 32 now. Your employer plan paid until you retired, and you've been buying 10 mg vials since. Under CMS's rule, your prescriber attests to the 37 — that meets the BMI part. But the Bridge won't pay for vials, so you'd need a KwikPen prescription. (Hypothetical example.) More: Medicare GLP-1 Bridge eligibility and why the Bridge doesn't cover Zepbound vials.

Medicaid

Medicaid coverage of Zepbound for weight loss depends on your state. Some keep a route for sleep apnea or medically necessary treatment under age 21. Read your state's notice and follow its hearing steps if you disagree. Check does Medicaid cover Zepbound and GLP-1 Medicaid coverage by state.

California's notice is one example: medically necessary requests for members under 21 can still be reviewed. It generally gives 90 days from the date of the denial notice to request a hearing. If you were taking the GLP-1 on or before January 1, 2026, requesting a hearing within 10 days after receiving a notice denying continued coverage may keep coverage in place until the earliest of your current approval's end, the hearing decision, or the case's withdrawal or closure. Those are California's rules, not every state's (Medi-Cal Rx notice).

TRICARE, VA, and other government plans

These have their own drug lists and approval rules, and they aren't part of the Medicare Bridge. See does TRICARE cover Zepbound and VA's formulary and pharmacy resources.

For Medicare, Medicaid, TRICARE, and VA coverage: Lilly's commercial $25 and $499 cards don't apply. Separate single-dose-vial or KwikPen cash offers may be available if you meet their terms. The KwikPen Self-Pay Card bars reimbursement and deductible or Part D out-of-pocket credit; check the exact terms for other cash purchases (Lilly savings; full terms). FEHB is a separate employer-plan route; check your own plan and the card rules.

If it stays uncovered, what will my next Zepbound refill cost?

Price the device and dose you're on now, not a starter deal. As of October 21, 2026, Lilly's eligible self-pay offers for Zepbound single-dose vials or KwikPens are $299 at 2.5 mg, $399 at 5 mg, and $449 at 7.5 to 15 mg. After the first eligible higher-dose purchase, buy within 45 days of delivery to keep $449. Outside that offer, higher doses cost $499 or $699. These are medicine-only prices.

Zepbound price map by situation and device

Per 28-day supply. Medicine only. Checked October 21, 2026.

LillyDirect posts the cash prices shown. With a retail KwikPen card, they are as low as prices: the pharmacy's charge and the card's savings limits can leave you paying more. Get the pharmacy's quote before buying.

Sources: Lilly full program terms (CMAT-05333, August 2026); LillyDirect; CMS.

The 2.5 mg dose is a starting dose, not a maintenance dose. Plan around the dose your prescriber expects you to stay on — for weight management, the label's maintenance doses are 5, 10, or 15 mg (label). Never change your dose to get a lower price.

What 13 fills would cost at today's prices

Thirteen 28-day fills contain 364 days of medicine. These are fixed-price illustrations, not a quote for the next 12 months: every purchase would need to remain eligible, and today's Lilly cards end December 31, 2026. Both KwikPen card programs allow at most 11 fills per calendar year. The late-purchase example spans more than 364 calendar days. These totals cover medicine only.

Look at rows one and two. Across 13 purchases at these prices, the two 10 mg examples differ by $3,000. That's a purchase-price comparison, not an annual savings promise. That's why the 45-day rule matters so much.

The fine print, in plain words

• The 45-day clock starts on the qualifying delivery day, not the day of your last shot. Set a phone reminder for day 30. Delivered October 1? Complete your next purchase by November 15 to keep $449. Traveling or changing doses? Call LillyDirect at 1-844-559-3471 before the window closes.
• Switching from insurance mid-treatment? Your first eligible cash-offer purchase at 7.5 mg or higher gets $449. The offer is open to new and existing patients who meet its terms.
• The KwikPen Self-Pay Card has a no-reimbursement rule. Purchases with that specific card can't be reimbursed by insurance, a healthcare reimbursement account, or another third party, and don't count toward your deductible or Part D out-of-pocket limit. For other cash purchases, check your plan and the exact offer terms.
• The $25 card needs coverage. It only works when your commercial plan covers the single-dose pen. It won't make an uncovered fill $25.
• Some employer plans block Lilly's cards. If your plan uses an "alternate funding program" that sends you to manufacturer help as a condition of coverage, you aren't eligible for Lilly's cards. Ask your plan.
• All current Lilly cards end December 31, 2026. Don't assume the 2027 version will match. Check Lilly's savings page before your first January fill.
• Lilly can change self-pay offers at any time, per its terms.
• Delivery is free; home delivery or Walmart Pharmacy pickup for single-dose vials and KwikPens (LillyDirect). Needles and syringes cost extra. An unknown fee isn't a $0 fee.
• HSA/FSA: LillyDirect says eligibility "may vary by plan." The separate KwikPen Self-Pay Card bars healthcare-account reimbursement, so do not assume a payment method makes that purchase reimbursable. Confirm the account rules and the exact offer first (is Zepbound HSA/FSA eligible).

Which device should I ask about?

Switching devices needs a new prescription and training. The label lists 0.5 mL per dose for single-dose pens and single-dose vials, and 0.6 mL for KwikPens and multi-dose vials. Follow the instructions for the device you're given (label). More in our Zepbound dose chart for pen, vial, and KwikPen.

If you already have a prescriber, you can see Lilly's prices and ordering steps on LillyDirect's Zepbound page (official Lilly site, not an affiliate link). For every other way to pay, see the cheapest Zepbound without insurance and LillyDirect vials vs. insurance.

What if I can't afford even that?

A lower cash price can still be out of reach. That's a real answer, not a failure. Tell your prescriber your actual monthly limit and ask which FDA-approved options your plan does cover. Other medicines have their own prices — for example, Ro lists Lilly's daily pill Foundayo from $149 a month and the Wegovy single-dose pen at $349 per 28 days for 1–2.4 mg; other strengths have different prices. Those are medication prices, plus Ro's membership (Ro pricing, checked October 21, 2026). They aren't the same as Zepbound, and whether one fits you is a medical decision. See best Zepbound alternatives and Foundayo vs. Zepbound.

Do I need a new provider?

Usually not to start. Your current prescriber can request a renewal, send records, and send a single-dose-vial or KwikPen prescription to LillyDirect. A new provider can't make an excluded drug covered. It makes sense if your doctor won't handle the paperwork, doesn't prescribe GLP-1s, or you want ongoing check-ins.

Ro fits two kinds of readers here: people with commercial insurance or FEHB whose plan still covers some GLP-1s and who want someone else to handle the prior authorization, and people paying cash who need a prescriber.

The honest catches first:

• Ro doesn't fix exclusions. If your plan dropped weight-loss drugs entirely, no paperwork changes that.
• Ro's Zepbound prices aren't lower. Its KwikPen cash offers match Lilly's — $299, $399, and conditional $449 by dose, with the same program limits — and Ro says its cash prices match LillyDirect. We did not verify a current Ro vial price.
• Ro's free coverage check covers pens, not the KwikPen. It checks the Zepbound single-dose pen, the Wegovy pen, and the Ozempic pen (Ro).
• Care is a paid membership, billed separately from medicine. Get started for $39, then as low as $74/month with annual plan paid upfront. That annual plan is $888 paid upfront — not a $74 monthly bill. Month to month, it's $149, which makes the first 12 months $1,678 plus medicine. Ro refunds the $39 if no medication is prescribed (Ro pricing; Ro terms).
• Cancel at least 48 hours before renewal to avoid the next charge. Apart from the no-prescription refund above, membership fees already paid are non-refundable. The membership keeps renewing even if you don't get medicine (Ro terms).

Where Ro helps is the part that eats your time. If a Ro clinician prescribes, its insurance team checks your benefits and handles prior authorization paperwork, usually in 1 to 3 weeks. If coverage isn't available, its providers can suggest FDA-approved cash-pay options (Ro insurance). Ro doesn't currently accept Medicaid members for treatment. Medicare, Medigap, and TRICARE members may qualify for certain cash-pay options; that is not a promise of treatment.

So here's the line: if you already have a prescriber who'll keep prescribing, go straight to LillyDirect and skip the membership. If you're not sure whether your plan covers the Zepbound pen again — especially after the CVS Caremark change — Ro's free check gives you a coverage report by email. You'll need to sign up and share your insurance card details. A report isn't an approval, and prescribing care is the separate paid membership above.

Check your Zepbound pen coverage with Ro

If your current doctor doesn't provide GLP-1 care and you'd pay cash for the KwikPen, a Ro clinician can review whether treatment fits you. You'd pay the applicable KwikPen medication price plus the membership; the higher-dose $449 offer still has Lilly's conditions.

See Ro's Zepbound KwikPen pricing

For more on how Ro handles denials, see does Ro appeal GLP-1 insurance denials and Ro vs. LillyDirect.

What about compounded tirzepatide?

Compounded tirzepatide is not Zepbound and is not FDA-approved. The FDA doesn't review compounded drugs for safety, effectiveness, or quality before they reach patients. The FDA declared the tirzepatide shortage over in late 2024, which ended the shortage exception that allowed routine copies.

A few facts to know before you consider it:

• The shortage rules are over. The FDA determined the tirzepatide shortage was resolved (October 2, 2024, reaffirmed December 19, 2024). Its grace periods ended in March 2025. Tirzepatide isn't on the FDA's shortage list or the list of bulk ingredients outsourcing facilities may use (FDA, current as of April 1, 2026).
• Copies are restricted. State-licensed pharmacies using the 503A pathway may not regularly make copies of a commercially available drug unless a prescriber documents a significant difference for a specific patient (same FDA page).
• The FDA has warned about risks, including dosing errors and fake products (FDA).
• Zepbound's studies don't carry over. SURMOUNT-4 and Zepbound's other trials don't establish the safety or effectiveness of any compounded product.

Losing insurance doesn't, by itself, mean a compounded drug is the right replacement. Price isn't a medical need. If your clinician identifies one and recommends a compounded option, read our Embody review and compounded vs. name-brand GLP-1s first.

Embody advertises compounded tirzepatide injections at $119 a month. Its published terms put that rate on the 12-month plan and list $129 for the monthly plan, including all doses, shipping, and provider visits. Twelve months at $119 adds up to $1,428; that is a calculated commitment, not a checkout total we observed. Its homepage describes 4-, 12-, 24-, or 52-week plans, prescribing by OpenLoop Health clinicians, and medicine from state-licensed 503A pharmacies (Embody). Confirm the exact supply period and billing schedule.

Multi-month plans aren't prorated. Cancel at least 72 hours before the next bill to avoid another charge. Payments are otherwise final, except that provider-initiated medical disqualification may qualify for an unused-portion refund, minus services already provided (refund policy, August 25, 2026). Embody says it serves all U.S. states except Louisiana; Nebraska users must be at least 19.

We couldn't confirm the total due today for each plan length or any referral-specific offer. Before paying, confirm that amount, the full commitment, renewal terms, the dispensing pharmacy, and availability for your exact treatment and state.

If your clinician has recommended a compounded option and you've read the limits above:

See Embody's current pricing

How we checked this page

On October 21, 2026, we read the primary documents and provider pages listed below and checked the math in these tables. The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation. Learn how we assess providers and treatment paths.

What we actually verified (October 21, 2026) | What we checked | What it confirms | What it can't tell you | |---|---|---| | Lilly's full Zepbound program terms (CMAT-05333, August 2026), LillyDirect page, and savings page | Self-pay prices, the 45-day purchase rule, separate card terms and fill limits, Dec 31, 2026 card end date, free delivery | Your final checkout total or your eligibility | | Zepbound prescribing information, revised August 2026 | Approved uses, maintenance doses, missed-dose guidance, four device presentations, contraindications | What your prescriber will decide for you | | CMS provider and Part D pages (modified August 6, 2026), pharmacy guidance, and Medicare.gov | $50 copay, KwikPen-only rule, eligibility, 2026 Part D rule, how approval works | Whether CMS approves you | | CVS announcements (May 1, 2025; May 28, 2026), IU's benefit notice (June 5, 2025), and Lilly's coverage page | The July 2025 change in affected plans and October 2026 return to common commercial lists | Whether your plan sponsor adopted either change | | CVS Caremark 6192-C, Cigna IP0816, Medi-Cal Rx notice | The published renewal rules, coverage changes, and exceptions described here | Your own benefit or approval | | GIC benefits guide and Mercer survey release (June 11, 2026) | GIC's different Medicare/non-Medicare dates; the 5% employer-survey figure | What any other employer will do | | Federal notice rules (29 CFR) and HealthCare.gov appeal/enrollment pages | Notice timing, standard appeal steps, and the loss-of-coverage enrollment window | Whether a rule covers your plan | | FDA compounding policy page (April 1, 2026 update) and unapproved-GLP-1 safety page | The FDA's published position on tirzepatide copies and reported risks | Whether any specific compounded product is safe or legal | | Ro pricing, coverage-check, insurance, and terms pages | Advertised fees, refunds, renewals, what the check covers (provider-stated) | Your checkout terms or approval odds | | Embody homepage, pricing terms (April 24, 2026), refund policy (August 25, 2026), and state-availability page | Published rates and commitments, cancel/refund terms, provider-stated availability | The referral offer, actual charge due today, or your dispensing pharmacy | We did not see your plan's decision, test treatment from any provider, or complete any checkout.

Questions about losing Zepbound coverage

Can insurance deny my Zepbound renewal because my BMI is lower now?

A lower BMI alone doesn't show whether you meet your plan's renewal rules. CVS Caremark's and Cigna's published policies consider starting weight and at least 5% loss or maintained loss, along with other criteria. Caremark's example requires three months at a stable maintenance dose; Cigna's continuation rule applies after eight completed months of initial treatment. Ask which rule failed and make sure the plan received your starting records.

Did CVS Caremark start covering Zepbound again?

Yes, for some plans. Zepbound returned to CVS Caremark's most common commercial drug lists as a preferred option on October 1, 2026, for employers and other plan sponsors that choose to cover weight-loss drugs. Check the Caremark portal for your exact device and ask HR or your plan whether it adopted the change.

Can I keep getting Zepbound if my insurance won't pay anymore?

Yes, if your prescriber keeps prescribing it and you choose a way to pay. Your current prescriber can send a single-dose-vial or KwikPen prescription to LillyDirect. Eligible cash offers are $299 to $449 per 28 days by dose; after the first higher-dose purchase, the next purchase must be within 45 days of delivery to keep $449. Without that offer, 7.5 mg is $499 and 10–15 mg is $699. You don't need a new provider to do this.

What's the cheapest way to stay on Zepbound without insurance?

The lowest Lilly cash prices we verified are for eligible single-dose-vial or KwikPen purchases: $299 at 2.5 mg, $399 at 5 mg, and $449 at 7.5 to 15 mg. After the first eligible higher-dose purchase, buy within 45 days of delivery to keep $449; otherwise, 7.5 mg is $499 and 10–15 mg is $699. Price your prescribed dose, not the starter dose. On Medicare, the Bridge charges $50 for the KwikPen if you qualify. Needles, syringes, prescriber fees, and any taxes or fees are extra.

Can I still use the Zepbound $25 savings card?

Only if your commercial plan covers the single-dose pen and you meet the card terms. It takes off up to $100 per 28-day fill; $25 is not guaranteed. If the pen isn't covered, the program may bring it to as low as $499 per 28 days. Those commercial offers exclude Medicare and Medicaid. The separate KwikPen Self-Pay Card has different eligibility and reimbursement rules. All current Lilly cards end December 31, 2026.

Does sleep apnea get Zepbound covered?

It can. Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity, and some plans that exclude weight loss still allow that use with a sleep study and prior authorization. It applies only if a clinician has diagnosed it, and approval isn't automatic.

Do I have to switch to Wegovy?

No one can make you switch medicines; your plan only decides what it pays for. If your plan prefers Wegovy, you can ask for a formulary exception, pay for Zepbound yourself, or talk with your prescriber about whether Wegovy fits you.

I'm on Medicare. Can I get Zepbound for $50?

Yes, if CMS approves you for the Medicare GLP-1 Bridge. It covers only the KwikPen for weight management. You need an eligible Part D plan, the BMI-at-start criteria, and the other clinical rules above. A GLP-1 prescription filled under Part D coverage in 2026 blocks access in 2026. Type 2 diabetes, moderate-to-severe obstructive sleep apnea, or MASH with moderate-to-advanced liver scarring but no cirrhosis also rule out this path. A Part D denial doesn't change that.

My prior authorization is still active. Can payment still stop?

Yes. An approval isn't a promise that every later claim will be paid. If the plan changed its benefit, its drug list, or your device, an approval with time left can stop working — Medi-Cal's December 31, 2025 cutoff is an example, but its notice includes under-21 and hearing exceptions.

What if I miss doses while I sort this out?

Check the current Zepbound label and ask your prescriber or pharmacist what to do about a missed dose. For a longer gap, ask your prescriber how to restart. Don't stretch or space out doses on your own.

Does paying cash count toward my deductible?

Not with the separate KwikPen Self-Pay Card: its terms bar reimbursement by insurance, healthcare reimbursement accounts, or other third parties, and bar deductible or Part D out-of-pocket credit. For other cash purchases, ask your plan and read that exact program's terms before assuming the receipt counts. A cash price alone doesn't answer this.

Is compounded tirzepatide the same as Zepbound?

No. Compounded drugs aren't FDA-approved, and the FDA doesn't review them for safety, effectiveness, or quality before they reach patients. Zepbound's study results don't apply to compounded products.

Sources

Primary documents and provider pages checked October 21, 2026. Separate publication and policy dates are shown.

• Lilly, Zepbound full terms and conditions (CMAT-05333, August 2026)
• Lilly, LillyDirect Zepbound page
• Lilly, Zepbound savings options
• Lilly, Zepbound access and coverage (updated September 30, 2026)
• Eli Lilly, Zepbound prescribing information (revised August 2026)
• Eli Lilly, Mounjaro prescribing information
• FDA, Foundayo prescribing information (2026 approval)
• Aronne LJ et al., SURMOUNT-4, JAMA 2024
• CMS, Medicare GLP-1 Bridge: Information for Providers (modified August 6, 2026)
• CMS, Medicare GLP-1 Bridge: Information for Part D Plans (modified August 6, 2026)
• CMS, Medicare GLP-1 Bridge: Information for Pharmacies
• Medicare.gov, Weight loss drugs
• CVS Health, CVS Caremark GLP-1 coverage options (May 28, 2026)
• CVS Health, First-quarter 2025 results and July formulary action (May 1, 2025)
• Indiana University Human Resources, CVS Caremark changes coverage for weight loss drug (June 5, 2025)
• CVS Caremark, Zepbound prior authorization criteria 6192-C
• Cigna, Zepbound coverage policy IP0816 (effective September 1, 2026)
• Medi-Cal Rx, GLP-1 coverage changes (effective January 1, 2026)
• Massachusetts Group Insurance Commission, 2026–2027 municipal benefits guide, page 3 (non-Medicare change after June 30, 2026; Medicare change after December 31, 2026)
• eCFR, 29 CFR 2520.104b-3 and 29 CFR 2590.715-2715
• HealthCare.gov, Internal appeals and Special Enrollment Period
• FDA, Policies for compounders as GLP-1 supply stabilizes (current as of April 1, 2026)
• FDA, Concerns with unapproved GLP-1 drugs used for weight loss
• Mercer, Employers are shifting healthcare costs to employees (June 11, 2026)
• The RX Index, GLP-1 employer coverage tracker (related research; original research cutoff September 25, 2026)
• Ro, Pricing, Free insurance check, Insurance, and Terms of use
• Embody, Published offering, Pricing terms (April 24, 2026), Refund policy (August 25, 2026), and State-availability page

Still not sure which GLP-1 path fits you? Take The RX Index's free Find My GLP-1 Path quiz — about 2 minutes, no signup.